Skip to main content
Log in

A Rapid Method of Screening for N-Acetyltransferase (NAT2) Phenotype by Use of the WAVE DNA Fragment Analysis System

  • Published:
Biochemical Genetics Aims and scope Submit manuscript

Abstract

N-Acetyltransferase 2 (NAT2) is involved in Phase II biotransformation of a variety of toxicants. Polymorphisms in the NAT2gene result in a slow acetylator phenotype, which has been associated with various cancers and neurodegenerative diseases. To date most studies investigating NAT2 genotype/phenotype have adopted an RFLP approach, which is both expensive and time-consuming. Using the Wave DNA fragment analysis system, we have developed a fast and robust method of identifying two polymorphisms (C282T and T341C) of the NAT2 gene which allows identification of the most common slow acetylator alleles found in Caucasian populations: NAT2*5, NAT2*6, NAT2*7, and NAT2*14. This was done by comparing phenotype status in 126 samples genotyped by RFLP analysis and also by Wave analysis for the polymorphisms C282T and T341C. All 126 samples analyzed by both RFLP and Wave analysis gave consistent phenotype results and 100% correlation was achieved between the two methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agundez, J. A. G., Jimenez-Jimenez, F. J., Luengo, A., Molina, J. A., Orti-Pareja, M., Vazquez, A., Ramos, F., Durst, J., Casia, J., Ladero, J., Averaz-Cermenoj, J., & Benitez, J. (1998). Slow Allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's Disease. Neurology 51:1587–1592.

    PubMed  Google Scholar 

  • Bandmann, O., Vaughan, J., Holmans, P., Marsden, C. D., & Wood, N. W. (1997). Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350:1136–1139.

    Google Scholar 

  • Brockmoller, J., Cascorbi, I., Kerb, R., Roots, I. (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione 5-transferase Ml and TI, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56:3915–3925.

    Google Scholar 

  • Cascorbi, I., Drakoulis, N., Brockmoller, J., Maurer, A., Sperling, K., Roots I. (1995). Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am. J. Hum. Genet. 57:581–592.

    Google Scholar 

  • Cascorbi, I., & Roots, I. (1998). Pitfalls in N-acetyltransferase genotyping. Pharmacogenetics 9:123–127.

    Google Scholar 

  • Doll, M. A., Fretland, Ad. J., Deitz, A. C., & David, W. H. (1995). Determination of human NAT2 acetylator genotype by restriction fragment-lengh polymorphism and allele specific amplification. Anal. Biochem. 231:413–420.

    Google Scholar 

  • Grant, D. M. (1993). Molecular genetics of the N-acetytransferases. Pharmacogenetics 3:45–50.

    Google Scholar 

  • Henning, S., Cascorbi, I., Munchow, B., Jahnke, V., Roots, I. (1999). Association of arylamine N-acetyltransferase NAT1 and NAT2 genotypes to larngeal cancer risk. Pharmacogenetics 9:103–111.

    Google Scholar 

  • Hirvonen, A., Saarkioski, S. T., Linnainmaa, K., Koskinen Kari, Husgafvel-Pursainen Kirsti, Mattson Karin, and Vainioh, H. (1996). Glutathione 5-transferase and N-acetyltransferase genotypes in asbestos-associated pulmonary disorders. J. Nat. Cancer Inst. 88:1853–1856.

    Google Scholar 

  • Mironova, N. J., Wilkman, H., Brouchardy, C., Mitrunen, K., Dayer, P., Benhamou, S., & Hirvonen, A. (1999). Role of arylamine N-acetltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 9:533–537.

    Google Scholar 

  • Risch, A., Wallace, D. M. A., Bathersa, S., Sim, E. (1995). Slow N-acetylation genotype is a susceptibilty factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4:231–236.

    Google Scholar 

  • Rocha, L., Garcia, C., de Medoca, A., Gil, J. P., Bishop, D. T., Lechner, M. C. (1999). N-Acetyltransferase (NAT2) genotype and susceptibility to sporadic Alzeimer's disease. Pharmacogenetics 9:9–15.

    PubMed  Google Scholar 

  • Smith, C. A. D., Wadelius, M., Gough A. C., Harrison, D. J., Roland, W. C., Rane, A. (1997). A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J. Med. Genet. 34:758–760.

    Google Scholar 

  • Taningher, M., Malcarne, D., Izzotti, A., Ugolini, D., Parodi, S. (1999). Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat. Res. 436:227–261.

    Google Scholar 

  • Underhill, P. A., Jin, L., Zemans, R., Oefner, P. J., Cavalli-Sforza, L. L. (1996). A pre-Columbian Y chromosome-specific transition and its implications for human evolutionary history. Proc. Natl. Acad. Sci. U.S.A. 93:196–200.

    Google Scholar 

  • Vatsis, K. P., Weber, W. W., Bell D. A., Dupret, J. M., Price-Evans, D. A., Grant, D. M., et al. (1995). Nomenclature for N-acetyltransferases. Pharmacogenetics 1:1–17.

    Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osborne, A., Bell, C., Grant, F. et al. A Rapid Method of Screening for N-Acetyltransferase (NAT2) Phenotype by Use of the WAVE DNA Fragment Analysis System. Biochem Genet 41, 405–411 (2003). https://doi.org/10.1023/B:BIGI.0000007775.61514.e8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BIGI.0000007775.61514.e8

Navigation